Louis Essandoh, MD, is a cardiologist at MedStar Cardiology Associates, Annapolis; a staff cardiologist at Anne Arundel Medical Center; and director, Cardiac Consultants, Annapolis. In addition to his clinical responsibilities, he is an assistant professor of Medicine (Cardiology) at the Johns Hopkins University School of Medicine.
Dr. Essandoh is the author of more than 30 peer-reviewed abstracts, original articles, and book chapters. He has served as principal investigator for more than 20 clinical trials on cardiovascular disease, hypertension, lipid abnormalities, heart failure, and atrial fibrillation. He acts as a consultant and serves on the speaker bureau for several major pharmaceutical companies. He is a fellow of the American College of Cardiology, the American College of Physicians, the American Society of Nuclear Cardiology, and the American College of Clinical Pharmacology. A past president of the American Heart Association’s Maryland Affiliate, he has also served as a board member for the American Heart Association’s Mid-Atlantic Affiliate.
He earned his medical degree at Yale University, where he also did postgraduate work in the Department of Engineering and Applied Sciences. Dr. Essandoh then completed a 6-year specialization in Internal Medicine and Cardiology at the Mayo Clinic, Rochester, MN. At Mayo, he was the first Charles E. Culpeper Foundation Fellow in the Medical Sciences.
Research Interests
Dr. Essandoh's research interests include
Clinical cardiology, including acute ischemic syndromes, heart failure and peripheral vascular diseaseCardiovascular clinical pharmacologyPreventive cardiologyCardiovascular clinical trialsNuclear cardiologyNeural control of the circulationExercise physiologySelected Research
Cardiovascular Inflammation Research Trial (CIRT)
Dr. Essandoh is a principal investigator for this randomized clinical trial funded by the National Heart, Lung, and Blood Institute. This trial is designed to investigate whether taking low-dose methotrexate reduces heart attacks, strokes or death in people with type 2 diabetes or metabolic syndrome and a history of heart attack or multiple coronary blockages.
Atrial Fibrillation Registry Trial
Dr. Essandoh is a principal investigator for this trial, called the Global Registry on Long-Term Oral Anti-Thrombotic Treatment In Patients With Atrial Fibrillation (GLORIA). This trial is sponsored by Boehringer Ingelheim.
A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome (ACS) Subjects (TRILOGY ACS)
Dr. Essandoh is a principal investigator on this trial sponsored by Eli Lilly and Company. This is a study of the efficacy and safety of prasugrel and clopidogrel in patients with medically managed unstable angina/non-ST-elevation myocardial infarction acute coronary syndrome.
Research Areas
- Cardiovascular